BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.

This study demonstrates that BP identifies tumors with two active functional pathways (dual subtype) with specific transcriptional characteristics and highlights the added value of distinguishing BP dual from single subtypes as evidenced by distinct treatment response rates.